

Serologic Responses to Nerve Antigens in Sooty Mangabey Monkeys with Experimental Leprosy¹

Sang-Nae Cho, Bobby J. Gormus, Keyu Xu, Rudolf P. Bohm, Jr.,
Gerald P. Walsh, Wayne M. Meyers, and Joo-Deuk Kim²

Nerve damage has been noted, with varying degrees of involvement, in virtually all leprosy patients. Although the pathogenic mechanisms of nerve destruction are not fully understood, antibodies to various nerve antigens have been implicated in the pathogenesis of nerve damage in leprosy (22, 27). However, whether or not antineural antibodies are significantly elevated in sera from leprosy patients is controversial (2, 5, 14, 23, 24, 27). In addition to technical differences between studies, this may be due partly to the fact that leprosy patients are diagnosed at different stages of the *Mycobacterium leprae* infection and have wide variations in nerve damage (3, 11, 18). Thus, it may be almost impossible to predict consistent relationships between antineural antibodies and the degree of nerve involvement in leprosy patients.

As a model of human leprosy, experimental animals such as armadillos and monkeys have been explored (13, 26). Sooty mangabey monkeys are reported to be an excellent model for leprosy, with clinical signs and humoral responses resembling human leprosy, including neurological deformities (6). In this study, serial serum samples, taken at regular intervals from mangabey monkeys before and after inoculation with *M. leprae*, were examined for antibodies to nerve tissue antigens such as ceramide, galactocerebroside (GC), and asialo-GM₁ (AGM₁).

The antineural antibodies were then compared with clinical findings, including nerve involvement before and after chemotherapy. In almost every animal, antibodies to one or more of the nerve antigens were elevated significantly 1 to 2 years prior to neurological deformities. In this study we present convincing evidence that antineural antibodies are produced during the course of *M. leprae* infection and are associated with clinical status and/or the development of subsequent nerve damage.

MATERIALS AND METHODS

Animals and *M. leprae* inoculation. Eight sooty mangabey monkeys (*Cercocebus torquatus atys*) were divided into four groups, two animals in each group. Each pair of mangabeys was inoculated intravenously and intracutaneously with a total dose of *M. leprae* ranging from 4.8×10^7 to 4.8×10^{10} (morphological index 10%) in one-log increments between groups. The biological history of mangabeys, the preparation of *M. leprae*, inoculation procedures, and clinical evaluations have been described in detail previously (6). When the animals needed treatment, rifampin was given at approximately 10 mg/kg daily.

Serum specimens. Serum specimens were obtained from mangabeys 2 months before inoculation and at intervals of approximately 3 months postinoculation (p.i.). Serum samples were stored frozen until used for detecting antineural antibodies.

Nerve antigens. Ceramide and GC antigens were prepared from formalinized human peripheral nerve tissues. After soaking the formalinized nerve tissue in distilled water for 3 days with several changes, the tissues were freeze-dried. Lipids were then extracted with a chloroform:methanol (2:1) solution. After washing with a chloroform:methanol:water (4:2:1) solution, the lipids were applied to a silica gel (70 to ap-

¹ Received for publication on 30 November 1992; accepted for publication in revised form on 24 March 1993.

² S.-N. Cho, D.V.M., Ph.D.; J.-D. Kim, M.D., Ph.D., Department of Microbiology, Yonsei University College of Medicine, C.P.O. Box 8044, Seoul 120-752, Republic of Korea. B. J. Gormus, Ph.D.; K. Xu, M.D., Department of Microbiology; R. P. Bohm, Jr., D.V.M., Department of Veterinary Sciences, Tulane Regional Primate Research Center, Covington, Louisiana 70433, U.S.A. G. P. Walsh, Ph.D., Leonard Wood Memorial Center for Leprosy Research, Cebu, The Philippines. W. M. Meyers, M.D., Ph.D., Armed Forces Institute of Pathology, Washington, D.C. 20306-6000, U.S.A.

proximately 230 mesh; Aldrich Chemical Co., Inc., Milwaukee, Wisconsin, U.S.A.) column and eluted with 2 bed volumes of chloroform, followed by 5%, 10%, and 20% (v/v) methanol in chloroform, respectively. Ceramide was identified from the lipid fraction eluted with 10% methanol and GC from the 20% methanol fraction, respectively, by comparing with standard ceramide and GC (Sigma Chemical Co., St. Louis, Missouri, U.S.A.) in thin-layer chromatography (TLC). Ceramide and GC antigens were then purified by preparative TLC. AGM₁ was obtained commercially from Sigma.

Detection of antibodies to nerve antigens. Antibodies to nerve antigens were detected using an enzyme-linked immunosorbent assay (ELISA) ⁽²⁵⁾ with minor modifications as previously described ⁽⁴⁾. Briefly, the nerve antigens were dissolved in ethanol at a 5.0 µg/ml concentration. A volume of 50 µl of each antigen was added to wells of a 96-well, U-bottom microtiter plate (Dynatech Laboratories, Inc., Alexandria, Virginia, U.S.A.), and incubated at room temperature until completely evaporated. The wells were then washed with phosphate buffered saline (PBS), pH 7.4, and blocked by the addition of 200 µl of PBS-0.5% (w/v) BSA (ICN ImmunoBiologicals, Lisle, Illinois, U.S.A.). After emptying the wells, 50 µl of serum diluted 1:200 in PBS-5% normal goat serum (NGS) (Gibco Laboratories, Grand Island, New York, U.S.A.) was added to the wells and incubated at 37°C for 90 min. This was followed by the addition of peroxidase-conjugated goat antihuman IgG or IgM (Cappel, Organonteknika Corp., West Chester, Pennsylvania, U.S.A.) diluted 1:3000 in PBS-5% NGS and of substrate solution, H₂O₂ + O-phenylenediamine. The absorbance was read at 490 nm.

Each serum was tested against all three antigens in the same plate. A pooled positive control serum was examined in each plate, and minor variations in the absorbances were corrected based on positive control values. Each test was performed in duplicate, and the absorbance of the wells without antigens was subtracted from those with the antigens before analysis.

RESULTS

Following inoculation of mangabey monkeys with *M. leprae*, serial serum specimens

were obtained and examined for antibodies to nerve antigens such as ceramide, GC, and AGM₁. The results were then compared with the clinical findings, especially for nerve involvement. Although both IgG and IgM antibodies to the antigens were investigated, only the ones which were elevated are shown in the figures. In general, there was no correlation between the inoculation doses of *M. leprae* and the antibody responses to the nerve antigens. Even between animals inoculated with the same doses of *M. leprae*, no consistent antibody responses to the nerve antigens were noted.

Mangabey D171, inoculated with 4.8×10^{10} *M. leprae*, developed lepromatous (LL)-type leprosy 5 months postinoculation (p.i.) and was treated at 38 months ⁽⁶⁾. In this mangabey, small peaks of IgG antibodies to ceramide and GC antigens appeared at 6 and 3 months p.i., respectively (Fig. 1A). The first major IgM antibody peaks appeared at 15 months, followed by the second major IgM antibody responses between 30 and 44 months p.i. After chemotherapy was initiated at 38 months, IgM antibodies to ceramide and GC remained at a high level for an additional 6 months and then declined sharply by 54 months p.i. Meanwhile, major peaks of IgG antibodies to the ceramide and GC antigens were shown at 21 months and were followed by another minor IgG peak at 42 months p.i. A small peak of IgM antibodies to AGM₁ was noted at 24 months only, and there were no significant IgG antibodies to the AGM₁ antigen noticeable throughout the study period. Despite early strong antineural antibody responses and clinical leprosy by 15 months, neurologic deformities appeared obvious only at 75 months and persisted beyond 105 months p.i. Therefore, antineural antibodies were detectable 60 months earlier than neurologic deformities in this animal.

In mangabey D172, also inoculated with 4.8×10^{10} *M. leprae*, clinical signs of disseminated lepromatous (LL) leprosy were found about 9 months p.i. and regressed spontaneously, but the disease recurred and regressed several times during the study period ⁽⁶⁾. Although antibody responses to the nerve antigens were not strong, there were several IgM antibody peaks to AGM₁ (Fig. 1B). Interestingly, the major antibodies to ceramide and GC were of the IgG class; no




FIG. 1. Longitudinal antibody responses to nerve antigens in mangabeys D171 (A) and D172 (B) before and at intervals after inoculation with 4.8×10^{10} *M. leprae*.

significant IgM antibodies to the antigens were noted in mangabey D172. Neurologic damage was first noted at 39 months p.i. and became progressively worse beyond 90 months p.i. even though chemotherapy was received at 65 months p.i.; neurologic deformities were shown beyond 90 months p.i. In this animal, antineural antibodies were detectable about 30 months before clinical nerve damage. Of particular interest, antibody to nerve antigens peaked about 5 months prior to the recurrence of clinical leprosy after a spontaneous remission of the initial disease at 9 months p.i.

Mangabey monkeys D173 and D174 were inoculated with 4.8×10^9 *M. leprae*. In

mangabey D173, early lesions of leprosy appeared 5 months p.i. but regressed by 14 months. At 86 months p.i., the first neurologic damage and bone absorption were noted, followed by progression of lepromatous (LL) leprosy. The animal required chemotherapy at 105 months p.i. This animal had significant IgM antibodies to AGM₁ before inoculation for unknown reasons, and had small fluctuations with low levels of antibodies (Fig. 2A). Meanwhile, there was a slight increase in IgG and IgM antibodies to ceramide at 3 months, but no major antibody response was shown until 63 months p.i. at which time there was a strong IgG antibody response to ceramide.




FIG. 2. Antibody responses to nerve antigens in mangabeys D173 (A) and D174 (B) before and at intervals after inoculation with 4.8×10^9 *M. leprae*.




FIG. 3. Antibody responses to nerve antigens in mangabeys D175 (A) and D176 (B) before and at intervals after inoculation with 4.8×10^8 *M. leprae*.

This was followed by a steady increase in IgM antibodies to ceramide and GC antigens which peaked at 85 months p.i., just 1 month before the first sign of neurologic damage. However, the IgM antibodies declined sharply within 4 months after onset of clinical nerve damage in the absence of chemotherapy. In this animal, therefore, a major antineural antibody peak was noted about 23 months prior to clinical nerve damage.

Mangabey D174 developed lepromatous (LL) leprosy by 10 months p.i. but regressed at 14 months. However, clinical signs of leprosy recurred in this animal at 35 months p.i. and persisted, requiring chemotherapy at 59 months. Neurologic deformities became obvious at 50 months and worsened after the initiation of chemotherapy. In this monkey, moderate levels of IgM antibodies to all three antigens appeared at 36 months p.i., coinciding with clinical reactivation, and were maintained until 63 months (Fig. 2B). Thus, antineural antibodies were detectable about 14 months earlier than neurological deformities, and the antibody levels decreased shortly after starting chemotherapy.

Mangabey D175, inoculated with 4.8×10^8 *M. leprae*, developed no clinical leprosy to date, 9 years p.i. There also has been no significant antibody response to the nerve antigens under investigation except for a small peak of IgM antibodies to ceramide at 59 months p.i. (Fig. 3A).

In mangabey D176, also inoculated with 4.8×10^8 *M. leprae*, lepromatous (LL) leprosy was noted at 4 months p.i., and the disease was extensive by 15 months. At 27 months p.i., rifampin treatment was initiated, resulting in complete remission at 35 months. There were strong IgM responses to ceramide and GC antigens at 15 months which lasted until 27 months p.i. (Fig. 3B). There were also small IgM antibody peaks to AGM₁ during the study period. Despite these strong antineural antibody responses, however, no neurological signs have been observed.

Mangabeys D177 and D178 received 4.8×10^7 *M. leprae*. In mangabey D177, there was a slow development of clinical leprosy (LLs) by 26 months p.i. At 42 months, treatment with rifampin was started. Nerve enlargement was first detectable at 47 months p.i. and persisted after successful chemotherapy. There were minor peaks of antibodies to ceramide which were followed by a strong IgG-antibody peak at 40 months p.i. (Fig. 4A). The antibodies to ceramide and GC declined after starting chemotherapy. Thus, antineural antibody responses appeared 7 months prior to palpable nerve enlargement.

In mangabey D178, an enlarged nerve was the first sign of leprosy at 35 months p.i. Histopathologically, there were indeterminate lesions of leprosy in the skin which later regressed spontaneously. However, neurological damage continued beyond 105




FIG. 4. Antibody responses to nerve antigens in mangabeys D177 (A) and D178 (B) before and at intervals after inoculation with 4.8×10^7 *M. leprae*.

months. No chemotherapy was given. Despite the presence of nerve enlargement, there were no major antibody responses to the three neural antigens except for a small peak of IgM antibody to AGM₁ at 37 months p.i., 2 months after the nerve enlargement was noticed (Fig. 4B).

The observations obtained in the eight animals are summarized in The Table. Of 8 mangabey monkeys inoculated with *M. leprae*, 7 animals had clinical leprosy; 6 of them had clinical evidence of damage to nerves—neurologic deformities and nerve enlargement. The median time for the initial signs of leprosy was 10 months (range 4 to 35 months). In contrast, nerve damage was noted rather late, about 35 to 86 months p.i. (median 54 months). The major immunoglobulin class to ceramide, GC and AGM₁ antigens was IgM, and the antibody responses to the nerve antigens were detectable from 15 to 63 months p.i. (median 37 months). Antineural antibodies were detectable at a mean of about 15 months (range -2 to 60 months). Thus, antineural antibodies appeared long before clinical evidence of nerve damage.

DISCUSSION

In this study, we present clear evidence that antineural antibodies are produced during the course of *M. leprae* infection. Consequently, the antineural antibodies appear to be indicative of future damage to nerves with neuropathic deformities. After

inoculation of mangabey monkeys with *M. leprae*, humoral antibody responses to *M. leprae* antigens, such as phenolic glycolipid (PGL)-I and lipoarabinomannan (LAM), appeared relatively early (3 to 6 months after infection^{6, 7}). In contrast, the median time for the first major peaks of antineural antibodies was 37 months p.i. (range 15 to 63 months). This was a rather late response considering that the initial signs of clinical leprosy appeared 5 to 10 months p.i. in the majority of the monkeys. This may, in turn, indicate that destruction of neural tissue proceeds slowly and, perhaps, is related to the slow growth rate of *M. leprae*. Once the nerve tissues are damaged by mechanisms which remain to be determined, the host's immune system appears to initiate antibody responses to the nerve antigens.

Of particular interest is that high levels of antibodies to nerve antigens were strongly associated with the onset and progress of clinical leprosy. For example, strong antineural antibody responses were found during rapid progression of the disease or development of extensive disease in mangabeys D171, D174, D176, and D177. In addition, an increase in antineural antibodies preceded by several months the recurrence of clinical leprosy or neurologic signs, as shown in mangabeys D172, D173 and D174. Therefore, one can assume that during the early stage of *M. leprae* infection, the bacterial load is not large and, despite clinical signs of leprosy, nerve involvement

may be very limited and, thus, may not be detectable during regular physical examination. Thus, by detecting antineural antibodies, it may be feasible to predict future clinical eruption of leprosy and/or nerve damage in persons infected with *M. leprae*.

There also seem to be several fluctuations of antineural antibody levels during the course of *M. leprae* infection in the absence of chemotherapy, as shown in mangabeys D171, D172, D173, and D177. This may imply that nerve tissues are destroyed intermittently, thus boosting antibody responses to the antigens. This suggests that there may be a wide variation in antineural antibody reactivity in sera from leprosy patients at the time of diagnosis, depending on the natural history of *M. leprae* infection in each patient.

In leprosy-endemic areas, many new leprosy patients are diagnosed with extensive disease long after initial signs have appeared. Since nerve damage is one of the cardinal signs of leprosy, almost all new leprosy patients have more or less nerve involvements, such as anesthesia, nerve enlargements and/or neurologic deformities, at the time of diagnosis (^{3, 18}). Therefore, it is not surprising that 40%–70% of new leprosy patients had elevated antibodies to ceramide, GC, or AGM₁ antigen. In addition, antineural antibodies are strongly associated with the extent of nerve involvement in leprosy patients at the time of diagnosis (²⁴; Cho, *et al.*, unpublished data).

As shown in this study, antineural antibodies were studied in leprosy patients in an attempt to elucidate the pathogenic mechanism(s) of nerve damage. This hypothesis was based on the concept that the antibodies may be directly involved in nerve tissue destruction, such as in Guillain-Barré syndrome (^{20, 21}), motor neuron diseases (^{16, 17}), systemic lupus erythematosus with neurological disorders (^{8, 19}), and multiple sclerosis (¹). Antibodies to GC, AGM₁, or other gangliosides have been reported to play a role in demyelination of the nerves in these diseases. However, although abnormal myelin changes were observed in nerve fibers (⁹), demyelination is not a prominent feature in leprosy. Rather, delayed-type hypersensitivity to *M. leprae* antigens in nerve tissues may provoke granuloma formation and destroy the nerves (^{10, 15}). Once the

THE TABLE. Clinical findings and antineural seroreactivity in mangabey monkeys inoculated with *M. leprae*.

	Mangabey monkey							
	D171	D172	D173	D174	D175	D176	D177	D178
Inoculum	4.8 × 10 ¹⁰	4.8 × 10 ¹⁰	4.8 × 10 ⁹	4.8 × 10 ⁹	4.8 × 10 ⁸	4.8 × 10 ⁸	4.8 × 10 ⁷	4.8 × 10 ⁷
Clinical leprosy ^a	LL	LL	LL	LL	No	LL	LL	I
Initial signs (mo.)	4–6	4–6	12	10	No	4–6	26	35
Nerve damage	Yes	Yes	Yes	Yes	No	No	Yes	Yes
Months	75	39	86	50			47	35
Nature	Deformity	Deformity	Deformity	Deformity			Enlarged	Enlarged
Antibody to								
Ceramide	IgG & M	IgG	IgG & M	IgM	IgM	IgG & M	IgG & M	—
GS	IgG & M	IgG	IgM	IgG & M	—	IgM	IgM	—
AGM ₁	IgM	IgM	IgM	IgM	—	IgM	IgM	IgM
Antibody peak (mo.)	15	21	63	36	59	18	40	37
Duration between antibody peak and nerve damage (mo.)	60	18	23	14	—	—	7	—2

^a LL = Lepromatous leprosy; I = indeterminate leprosy.

nerves are damaged, humoral antibody responses to nerve tissue antigens would undoubtedly follow, resulting in high antineural antibody levels.

During hypersensitivity as seen in lepra reactions (e.g., erythema nodosum leprosum or reversal or upgrading reactions), immediate nerve pain or damage will be noted, but in a majority of leprosy patients, a slow progress of nerve destruction will occur⁽¹²⁾ and eventually result in neurologic deformity, as seen in experimentally infected mangabey monkeys in this study. Therefore, despite hypersensitivity perhaps being the initial trigger of nerve damage along with *M. leprae* growth in the tissues, antineural antibodies still may be associated with the autoimmune-mediated destruction of nerve trunks leading to neurological deformities or nerve enlargement⁽²²⁾. Further study is warranted to explain the exact role of antineural antibodies in the pathogenesis of leprosy. Meantime, the detection of antibodies to nerve tissue antigens may be used for the assessment of leprosy patients by providing information on the degree of nerve tissue damage. Antineural antibody reactivity could be used as a parameter for the diagnosis of leprosy if combined with tools detecting *M. leprae* infection using *M. leprae*-specific antigens such as PGL-I⁽⁴⁾.

In this study, we inoculated a relatively large number of *M. leprae* compared to the dose presumed to be involved in the natural transmission of leprosy between animals or between leprosy patients and their contacts. Therefore, we do not know how to extrapolate precisely the clinical course of leprosy from these mangabey monkeys to human leprosy. However, as far as antibody responses to nerve antigens are concerned, this study produced unequivocal evidence that antineural antibodies usually preceded neurologic deformities or other neuropathologic events. It remains to be determined if these antibodies to nerve antigens are just bystander responses or if they play a role in the pathogenesis of nerve damage.

SUMMARY

Eight sooty mangabey monkeys were inoculated intravenously and intradermally with varying doses of *Mycobacterium leprae* from 4.8×10^7 to 4.8×10^{10} . Serum samples were obtained from the animals at in-

tervals of about 3 months for 90 months, and were examined for IgM and IgG antibodies to nerve antigens, including ceramide, galactocerebroside (GC), and asialo-GM₁ (AGM₁), using an enzyme-linked immunosorbent assay (ELISA). The serological results were then compared with clinical findings, particularly nerve involvement. Of 8 mangabey monkeys inoculated with *M. leprae*, 7 animals had clinical leprosy; 6 of them had nerve damage, including neurologic deformities in 4 monkeys and nerve enlargement in 2. Median time for the initial signs of leprosy was 10 months postinoculation (p.i.), a range from 4 to 35 months. In contrast, nerve damage was noted rather late, about 35 to 86 months p.i. (median 54 months). The major immunoglobulin class to ceramide, GC, and AGM₁ antigens was IgM, and the antibody responses to the nerve antigens appeared from 15 to 63 months p.i. (median 37 months). Antineural antibodies were thus detectable about 18 months (range -2 to 60 months) prior to observable nerve damage. In addition, elevation of antineural antibody levels were predictive of clinical exacerbation of the disease and neuritic damage. This study suggests that antineural antibodies are produced during the course of *M. leprae* infection and may be indicative of nerve damage, such as neurological deformities or nerve enlargement, in leprosy patients.

RESUMEN

Se inocularon 8 monos mangabey pardos con diferentes cantidades de *Mycobacterium leprae* (de 4.8×10^7 a 4.8×10^{10}) por las vías intravenosa e intradérmica. Después, a intervalos de 3 meses, se obtuvieron muestras de suero durante 90 meses, y en los sueros se buscaron anticuerpos IgM e IgG contra antígenos del sistema nervioso, incluyendo un cerámico, un galactocerebrósido (GC), y un asialo-GM₁ (AGM₁), usando un inmunoensayo enzimático (ELISA). Los resultados serológicos se compararon con los hallazgos clínicos, particularmente con el daño a nervios. De los 8 monos mangabey inoculados con *M. leprae*, 7 animales desarrollaron la enfermedad: 6 de ellos mostraron daño a nervios, incluyendo deformidades neurológicas en 4 monos y engrosamiento nervioso en 2 de ellos. El tiempo promedio de aparición de los síntomas de la lepra fue de 10 meses postinoculación (p.i.), con un rango de 4 a 35 meses. En contraste, el daño a nervios se notó más tardíamente, entre los 35 y los 86 meses p.i. (mediana d3 54 meses). La inmunoglobulina predominante contra los tres antígenos (cerámico, GC y

AGM₁) fue de la clase IgM, y las respuestas en anticuerpos contra los antígenos aparecieron entre los 15 y los 63 meses p.i. (mediana de 37 meses). Así, los anticuerpos antineurales fueron detectados aproximadamente 18 meses (rango de -2 a 60 meses) antes de la aparición clínica del daño a nervios. Además, la elevación de los niveles de anticuerpos antineurales fue predictiva de la exacerbación clínica de la enfermedad y del daño neurítico. Este estudio sugiere que los anticuerpos antineurales se producen durante el curso de la infección por el *M. leprae* y que su presencia puede ser indicativa del daño a nervios. Esto podría ocurrir en los pacientes con lepra que muestran alteraciones neurológicas o engrosamiento de nervios.

RÉSUMÉ

On a inoculé huit singes mangabey par voies intra-veineuse et intradermique avec du *Mycobacterium leprae* à des doses variant de $4,8 \times 10^7$ à $4,8 \times 10^{10}$. On a prélevé des échantillons de serum chez les animaux à intervalles d'environ trois mois durant nonante mois, et on a recherché la présence d'anticorps IgG et IgM vis-à-vis d'antigènes nerveux, y compris le ceramide, le galactoceroside (GC) et l'asialo-GM₁ (AGM₁) par un test immuno-enzymatique (ELISA). Les résultats sérologiques ont été comparés avec les observations cliniques, en particulier l'atteinte nerveuse. Parmi les huit singes mangabey inoculés avec du *M. leprae*, sept avaient une lèpre clinique; six d'entre eux avaient une atteinte nerveuse, avec des déformités d'origine neurologique chez quatre singes et un épaississement de nerfs chez deux d'entre eux. L'intervalle de temps médian pour l'apparition des premiers signes de lèpre suite à l'inoculation était de 10 mois, allant de 4 à 35 mois. Par contre, l'atteinte nerveuse a été notée plutôt tardivement, environ 35 à 86 mois après l'inoculation (médiane 54 mois). La principale classe d'immunoglobulines vis-à-vis des antigènes ceramide, GC, et AGM₁ était du type IgM et les réponses par anticorps aux antigènes nerveux sont apparus entre le quinzième et le soixante-troisième mois après l'inoculation (médiane 37 mois). Des anticorps dirigés contre les nerfs étaient donc détectables environ 18 mois (de 2 à 60 mois) avant qu'on puisse observer des dégâts nerveux. De plus, une augmentation des taux d'anticorps vis-à-vis des nerfs prédisait une exacerbation clinique de la maladie et une détérioration nerveuse. Cette étude suggère que des anticorps vis-à-vis des nerfs sont produits dans le décours de l'infection par *M. leprae* et peuvent indiquer une atteinte nerveuse chez les malades de la lèpre, telle que des déformités d'origine neurologique ou un épaississement des nerfs.

Acknowledgment. This work was supported in part by grants from the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases and from the National Institutes of Health grants #AI19302 from the National Institutes of Allergy and Infectious Diseases and #RR00164 from the Animal Resources Program, National Center for Research Re-

sources. The authors thank E. O. Shin and M. K. Lee for technical assistance.

REFERENCES

1. ARNON, R., CRISP, E., KELLEY, R., ELLISON, G. W., MYERS, L. W. and TOURTELLOTT, W. W. Anti-ganglioside antibodies in multiple sclerosis. *J. Neurol. Sci.* **46** (1980) 179-186.
2. BENJAMINS, J. A., CALLAHAN, R. E., RUNFT, D., GERRAS, G. and LEFFORD, M. J. Anti-neural antibodies in leprosy sera: further characterization of the antigens. *J. Neuroimmunol.* **21** (1989) 125-135.
3. CHAROSKY, C. B., GATTI, J. C. and CARDAMA, J. E. Neuropathies in Hansen's disease. (Editorial) *Int. J. Lepr.* **51** (1983) 576-586.
4. CHO, S.-N., YANAGIHARA, D. L., HUNTER, S. W., GELBER, R. H. and BRENNAN, P. J. Serological specificity of phenolic glycolipid I from *Mycobacterium leprae* and use in serodiagnosis of leprosy. *Infect. Immun.* **41** (1983) 1077-1083.
5. GHASWALA, P. S., MISTRY, N. F. and ANTIA, N. H. Serum antibodies of normals and leprosy patients show equal binding to peripheral nerve. *Int. J. Lepr.* **57** (1989) 690-692.
6. GORMUS, B. J., OHASHI, D. K., OHKAWA, S., WALSH, G. P., MEYERS, W. M., BRENNAN, P. J. and TRYGG, C. Serologic responses to *Mycobacterium leprae*-specific phenolic glycolipid-I antigen in sooty mangabey monkeys with experimental leprosy. *Int. J. Lepr.* **56** (1988) 537-545.
7. GORMUS, B. J., XU, K., MEYERS, W. M., WALSH, G. P., LEVY, W. R. and MEEKER, H. C. Antibodies to lipoarabinomannan antigen in sooty mangabey monkeys experimentally inoculated with *Mycobacterium leprae*. *Int. J. Lepr.* **58** (1990) 65-72.
8. HIRANO, T., HASHIMOTO, H., SHIOKAWA, Y., IWAMORI, M., NAGAI, Y., KASAI, M., OCHIAI, Y. and OKUMURA, K. Antiglycolipid autoantibody detected in the sera from systemic lupus erythematosus patients. *J. Clin. Invest.* **66** (1980) 1437-1440.
9. JACOBS, J. M., SHETTY, W. P. and ANTIA, N. H. Myelin changes in leprosy neuropathy. *Acta Neuropathol.* **74** (1987) 75-80.
10. JOB, C. K. Mechanism of nerve destruction in tuberculoid-borderline leprosy; an electron-microscopic study. *J. Neurol. Sci.* **20** (1973) 25-38.
11. JOB, C. K. Nerve damage in leprosy. *Int. J. Lepr.* **57** (1989) 532-539.
12. JOB, C. K., VICTOR, D. B. I. and CHACKO, C. J. G. Progressive nerve lesion in a disease-arrested leprosy patient; an electron microscopic study. *Int. J. Lepr.* **45** (1977) 255-260.
13. KIRCHHEIMER, W. F. and STORRS, E. E. Attempts to establish the armadillo (*Dasypus novemcinctus* Linn.) as a model for the study of leprosy. I. Report of lepromatoid leprosy in an experimentally infected armadillo. *Int. J. Lepr.* **39** (1971) 693-702.

14. MSHANA, R. N., HARBOE, M., STONER, G. L., HUGHES, R. A. C., KADLUBOWSKI, M. and BELEHU, A. Immune responses to bovine neural antigens in leprosy patients. I. Absence of antibodies to an isolated myelin protein. *Int. J. Lepr.* **51** (1983) 33–40.
15. MSHANA, R. N., HUMBER, D. P., HARBOE, M. and BELEHU, A. Nerve damage following intraneural injection of *Mycobacterium leprae* into rabbits pre-sensitized to mycobacteria. *Clin. Exp. Immunol.* **52** (1983) 441–448.
16. NOBILE-ORAZIO, E., CARPO, M., LEGNAME, G., MEUCCI, N., SONNINO, S. and SCARLATO, G. Anti-GM1 IgM antibodies in motor neuron disease and neuropathy. *Neurology* **40** (1990) 1747–1750.
17. PESTRONK, A., CHAUDHRY, V., FELDMAN, E. L., GRIFFIN, J. W., CORNBATH, D. R., DENYS, E. H., GLASBERG, M., KUNCL, R. W., OLNEY, R. K. and YEE, W. C. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. *Ann. Neurol.* **27** (1990) 316–326.
18. RIDLEY, D. S. and JOPLING, W. H. Classification of leprosy according to immunity; a five-group system. *Int. J. Lepr.* **34** (1966) 255–273.
19. ROBBINS, M. L., KORNGUTH, S. E., BELL, C. L., KALINKE, T., ENGLAND, D., TURSKI, P. and GRAZIANO, F. M. Antineurofilament antibody evaluation in neuropsychiatric systemic lupus erythematosus. *Arthritis Rheum.* **31** (1988) 623–631.
20. RYBERG, B., HINDFELT, B., NILSSON, B. and OLSSON, J. E. Antineural antibodies in Guillain-Barré syndrome and lymphocytic meningoradiculitis (Bannwarth's syndrome). *Arch. Neurol.* **41** (1984) 1277–1281.
21. SAIDA, T., SAIDA, K., LISAK, R. P., BROWN, M. J., SILBERBERG, D. H. and ASBURY, A. K. *In vitro* demyelinating activity of sera from patients with Guillain-Barré syndrome. *Ann. Neurol.* **11** (1982) 69–75.
22. SHETTY, V. P., MISTRY, N. F. and ANTIA, N. H. Serum demyelinating factors and adjuvant-like activity of *Mycobacterium leprae*: possible causes of early nerve damage in leprosy. *Lepr. Rev.* **56** (1985) 221–227.
23. THOMAS, B. M. and MUKHERJEE, R. Antineural antibodies in sera of leprosy patients. *Clin. Immunol. Immunopathol.* **57** (1990) 420–429.
24. VEMURI, N. and MUKHERJEE, R. Immunoreactivity of nerve lipid antigens in leprosy. *J. Clin. Lab. Anal.* **5** (1991) 157–161.
25. VOLLER, A., BIDWELL, D. E. and BARTLETT, A. *The Enzyme-linked Immunosorbent Assay (ELISA)*. Alexandria, Virginia, U.S.A.: Dynatech Laboratories, Inc., 1979.
26. WOLF, R. H., GORMUS, B. J., MARTIN, L. N., BASKIN, G. B., WALSH, G. P., MEYERS, W. M. and BINFORD, C. H. Experimental leprosy in three species of monkeys. *Science* **227** (1985) 529–531.
27. WRIGHT, D. J. M., HIRST, R. A. and WATERS, M. F. R. Neural autoantibodies in leprosy. *Lepr. Rev.* **46** (1975) 157–169.